Related Experiment Video
Updated: Aug 21, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Application of the PDCA cycle in companion diagnostic PD-L1 SP263 immunohistochemical testing
Xiaoying Liu1, Feicheng Yang1, Kun Wang1
1Department of Pathology, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Changsha, 410005, China.
Abstract:
The aim of this study was to investigate application of the PDCA (Plan-Do-Check-Action) cycle in companion diagnostic PD-L1 SP263 immunohistochemical (IHC) testing. By using scientific quality control methods, the accuracy and consistency of the experimental results were ensured.Methods A total of 279 cases of PD-L1 SP263 IHC testing conducted in our hospital from May 2021 to December 2021 were collected. The PDCA cycle method was applied, and quality control data before and after its implementation were analyzed and compared.Results The application of the PDCA cycle effectively strengthened quality control management that significantly improved the accuracy and consistency of PD-L1 SP263 IHC testing results.Conclusion PD-L1 SP263 testing has value as both a complementary and companion diagnostic test for immunotherapy in malignant tumors, with the accuracy of its results being particularly crucial. The testing process involves pre-analytical, analytical, and post-analytical phases. The application of the PDCA cycle provides a robust scientific approach to aid quality control management throughout the PD-L1 SP263 testing process.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023